Article
FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia.
Seminars in hematology - 1 Jul 2015
Grunwald Michael R, Levis Mark J
Abstract excerpt
Therapy targeting specific somatic mutations has become an increasingly important part of cancer therapy over the past 20 years. In particular, tyrosine kinase inhibitors (TKIs) have become a critical component of treatment for both solid tumors and hematologic malignancies. Since mutations in th...
Topics
- Drug Design
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Nucleophosmin
- Protein Kinase Inhibitors
- Signal Transduction
- fms-Like Tyrosine Kinase 3